ArticleClinical and translational radiation oncology2026
Radiotherapy quality assurance in the Danish breast cancer Group RT Natural trial.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose/Objective: Partial breast irradiation (PBI) is standard for selected relatively low-risk breast cancer patients, aiming to minimise late effects while maintaining local control. The Danish Breast Cancer Group (DBCG) RT Natural trial investigated whether PBI could be safely omitted in selected patients. Here, we report the radiotherapy quality assurance in the trial, evaluating target coverage and doses to organs of interest against protocol criteria. Material/Methods: Eligible patients were women ≥ 60 years with T ≤ 20 mm, unilateral, unifocal, node-negative, hormone receptor-positive, HER2-normal, non-lobular invasive breast cancer. Patients were randomised 1:1 to PBI (40 Gy in 15 fractions) versus no radiotherapy. Treatment plans for all patients treated with PBI were prospectively collected in a centralised DICOM-RT database and evaluated for protocol compliance. Results: Data from the 238 patients receiving PBI were analysed. Dose coverage was high, with median V95% of 100% for the tumour bed and CTVp_PBI and 98% for the PTVp_PBI. Only 1% had a CTVp_PBI V95% below the intended 95%, whereas 22% had a PTVp_PBI V95% <95%. No patients exceeded 110% of the prescribed dose. Dose conformity was good with median whole-breast V40Gy of 21%.Ipsilateral median mean lung dose was 1.52 Gy, and median mean heart dose 0.25 Gy left / 0.12 Gy right with no violation of dose guidance. Respiratory gating did not significantly affect lung or heart doses. Conclusion: PBI in the DBCG RT Natural trial provided robust target coverage with minimal high-dose volumes, and maintained low cardiac and pulmonary doses, consistent with protocol planning objectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.